血必净注射液治疗急性胰腺炎的系统评价再评价
该研究对9项系统评价(含92项随机对照试验、6837例参与者)进行再评价,评估血必净注射液治疗急性胰腺炎(AP)或重症急性胰腺炎(SAP)的疗效与安全性。方法学质量多为低或极低,GRADE证据仅5项结局为中等质量。数据合成显示血必净联合治疗可提高总有效率(RR=1.19,95%CI 1.17-1.23,p<0.0001),缩短腹痛和腹胀缓解时间,降低血清淀粉酶水平。
要点
- 血必净联合治疗可提高AP患者总有效率,RR=1.19(95%CI 1.17-1.23)。
- 血必净可缩短腹痛缓解时间(WMD=-1.69)和腹胀缓解时间(WMD=-1.48)。
- 血必净可降低血清淀粉酶水平(WMD=-2.06),但证据质量多为低或极低。
核心结论
- 尽管证据质量不高,血必净注射液作为镇痛和抗炎中药在AP/SAP治疗中仍体现临床价值。
- 未来临床研究应关注药物的长期疗效和不良反应。
研究设计与样本
- 纳入9项合格系统评价,包含92项随机对照试验、6837例参与者。
- 采用AMSTAR-2和PRISMA评价方法学与报告质量,GRADE评价结局证据质量,ROBIS评价偏倚风险。
- 使用Stata15.1对总有效率、腹痛缓解时间、腹胀缓解时间和血清淀粉酶水平进行定量分析。
主要发现
- 血必净联合治疗提高AP患者总有效率(RR=1.19,95%CI 1.17-1.23,p<0.0001),异质性I2=0.0%(p=0.589)。
- 血必净组缩短腹痛缓解时间(WMD=-1.69,95%CI -1.88至-1.50,p<0.0001),异质性I2=84.3%(p=0.000)。
- 血必净组缩短腹胀缓解时间(WMD=-1.48,95%CI -1.74至-1.23,p<0.0001),异质性I2=72.2%(p=0.000)。
- 血必净组降低血清淀粉酶水平(WMD=-2.06,95%CI -2.47至-1.64,p<0.0001),异质性I2=71.6%(p=0.000)。
- 1项系统评价报告了不良反应,对照组未观察到不良反应。
关键数值与推荐
- AMSTAR-2评价显示系统评价方法学质量低或极低。
- ROBIS评价5项系统评价为低偏倚风险,4项为高偏倚风险。
- GRADE评价共47项结局:5项(10.64%)为中等质量,22项(46.81%)为低质量,20项(42.55%)为极低质量。
临床怎么用
- 血必净注射液联合常规治疗可能提高AP患者总有效率并加速症状缓解。
- 临床应用需结合证据质量低下的现状,关注长期疗效和不良反应监测。
局限性
- 纳入系统评价的方法学质量低或极低,GRADE证据多为低或极低质量。
- 腹痛、腹胀缓解时间和血清淀粉酶水平的合并结果存在显著异质性。
- 仅1项系统评价报告了不良反应,安全性信息有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: At present, a number of systematic reviews (SRs) on Xuebijing injection (a patent in China) in the treatment of acute pancreatitis (AP) or severe acute pancreatitis (SAP) have been published. However, the quality of evidence is uneven and has not been comprehensively evaluated. Aim: We evaluated the efficacy of Xuebijing injection for AP/SAP through an overview of SR, and to provide a scientific basis for its effectiveness and safety. Methods: We searched Cochrane Library, Embase, PubMed, SinoMed, CNKI, Wanfang, and VIP comprehensively. The retrieval period from inception to 30 November 2021, and the two reviewers independently complete the literature retrieval, data extraction and evaluation. The Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR-2) and the Preferred Reporting Item for Systematic Review and Meta-analysis (PRISMA) were used to evaluate the methodological quality and reporting quality of the SRs, respectively. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool was used to evaluate the quality grading of outcomes and the risk of bias in SRs was evaluated by ROBIS Tool. Finally, the RCTs involved in SRs were synthesized. Stata15.1 was used for quantitative analysis of total effectiveness rate, time until relief of abdominal pain, time until relief of abdominal distension, and serum amylase level. Results: Nine eligible SRs were included, including 92 RCTs and 6,837 participants. The quality of SRs was relatively good, and the manuscript structures were relatively complete. However, the methodological quality of SRs was low or critically low. RoB rated 5 SRs as low risk of bias and 4 SRs as high risk of bias. In GRADE, a total of 47 results were included in the 9 SRs, of which 5 results (10.64%) were moderate quality, 22 results (46.81%) were low quality, and 20 results (42.55%) were very low quality. The results of data synthesis showed that Xuebijing injection combined treatment increased the total effectiveness rate of AP patients (RR = 1.19, 95% CI 1.17-1.23, p < 0.0001), and there was no heterogeneity between studies (I2 = 0.0%, p = 0.589). Compared with the control group, Xuebijing injection group shortened the abdominal pain and distension relief time in AP patients (WMD = -1.69, 95% CI -1.88--1.50, p < 0.0001; WMD = -1.48, 95% CI -1.74--1.23, p < 0.0001), with high heterogeneity (I2 = 84.3%, p = 0.000; I2 = 72.2%, p = 0.000). Serum amylase level was also reduced (WMD = -2.06, 95% CI -2.47--1.64, p < 0.0001), with significant heterogeneity (I2 = 71.6%, p = 0.000). A total of one SR reported adverse drug reaction (ADR), no ADRs were observed in the control group. Conclusion: Although the quality of the evidence is not high, it can still reflect the clinical value of Xuebijing injection as an analgesic and anti-inflammatory traditional Chinese medicine in the treatment of AP/SAP. Therefore, future clinical studies should focus on the long-term efficacy and adverse reactions of drugs. Systematic Review Registration: (website), identifier (registration number).
引用
- Zhu F, Yin S, Zhou L, et al. Chinese herbal medicine xuebijing injection for acute pancreatitis: An overview of systematic reviews. Front Pharmacol. 2022. PMID: 36034818. doi:10.3389/fphar.2022.883729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。